FDA Inspection Readiness Checklist for BIMO Sponsors and CROs

FDA inspection readiness checklist infographic for BIMO sponsors and CROs covering governance, records, oversight, participant protection, data integrity, interviews, and CAPA readiness.

An FDA inspection readiness checklist should test whether sponsors and CROs can demonstrate control of people, records, oversight, participant protection, data integrity, and remediation. This BIMO-focused framework helps clinical quality and operations teams identify evidence gaps, owners, and red flags before inspection pressure rises.

Clinical Trial Audit Checklist for CRO and Vendor Oversight

Clinical trial audit checklist infographic for CRO and vendor oversight showing audit scope, evidence, sponsor oversight, red flags, CAPA, and risk-based audit priorities.

A clinical trial audit checklist should help sponsors test whether CROs, vendors, sites, and critical processes are operating as intended under GCP. This risk-based checklist organizes audit scope, evidence, ownership, red flags, findings, and follow-up for outsourced clinical trials.

CAPA Effectiveness Check Checklist for Clinical Quality Teams

CAPA effectiveness check infographic for clinical quality teams showing finding definition, root cause, implementation, evidence, recurrence, residual risk, and closure decisions.

CAPA effectiveness checks should prove that clinical corrective actions worked, not simply that tasks were completed. This sponsor-side checklist helps Clinical Quality and Clinical Operations define evidence, owners, red flags, recurrence review, residual risk, and closure decisions.

IND Submission Content Checklist: What Sponsors Need Before Authoring Begins

Senior regulatory professional reviewing regulatory submission documentation for a life sciences development program

Heads or VPs of Regulatory Affairs Regulatory Operations leaders Chief Medical Officers Clinical development leaders coordinating an initial IND Emerging biotech teams preparing for their first major FDA filing It is most useful from late IND-enabling development through preparation of the initial IND, although the same principles apply to later regulatory submissions. The checklist does […]